The role of von Willebrand factor and ADAMTS13 in the no-reflow phenomenon: After primary percutaneous coronary intervention

Texas Heart Institute Journal

Volumn 38, Issue 5, 2011, Pages 516-522

  Zhao, Bilian ^a   Li, Jian ^a   Luo, Xinping ^a   Zhou, Qing ^a   Chen, Hua ^a   Shi, Haiming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

ADAMTS13 protein; Angioplasty; Balloon; Coronary adverse effects; Human; Microcirculation; Myocardial ischemia; Myocardial reperfusion; No reflow phenomenon drug therapy; Predictive value of tests; Prospective studies; Von willebrand factor

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ADAM PROTEINS; AGED; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CHINA; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NO-REFLOW PHENOMENON; ODDS RATIO; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; TIME FACTORS; UP-REGULATION; VON WILLEBRAND FACTOR;

EID: 83455199985     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Reffelmann T, Kloner RA. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 2006;101(5):359-72.
2. Ito H. No-reflow phenomenon in patients with acute myocardial infarction: its pathophysiology and clinical implications. Acta Med Okayama 2009;63(4):161-8.
3. Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol 2009;54(4):281-92.
4. Ndrepepa G, Tiroch K, Keta D, Fusaro M, Seyfarth M, Pache J, et al. Predictive factors and impact of no reflow after prima- ry percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 2010;3(1):27-33.
5. Kiernan TJ, Ruggiero NJ 2nd, Bernal JM, Don CW, Witzke C, Kiernan GD, et al. The no-reflow phenomenon in the coronary circulation. Cardiovasc Hematol Agents Med Chem 2009;7(3):181-92.
6. Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Tei C, et al. The white blood cell count is an independent predictor of no-reflow and mortality following acute myocardial infarction in the coronary interventional era. Ann Med 2004; 36(2):153-60.
7. Haeck JD, Verouden NJ, Henriques JP, Koch KT. Current status of distal embolization in percutaneous coronary intervention: mechanical and pharmacological strategies. Future Cardiol 2009;5(4):385-402.
8. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996;88(8):2939-50.
9. Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem 2000;275(11): 7539-46.
10. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Wille brand factor. Cell 1996;84(2):289-97.
11. Fredrickson BJ, Dong JF, McIntire LV, Lopez JA. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-IX-V complex. Blood 1998;92(10):3684-93.
12. Mendolicchio GL, Ruggeri ZM. New perspectives on von Willebrand factor functions in hemostasis and thrombosis. Semin Hematol 2005;42(1):5-14.
13. Tsai HM. ADAMTS13 and microvascular thrombosis. Expert Rev Cardiovasc Ther 2006;4(6):813-25.
14. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002;105(5):656-62.
15. Reffelmann T, Kloner RA. The "no-reflow" phenomenon: basic science and clinical correlates. Heart 2002;87(2):162-8.
16. Sgueglia GA, Niccoli G, Spaziani C, Cosentino N, Russo E, Andreotti F, et al. Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary percutaneous coronary intervention for ST segment elevation myocardial infarction. Int J Cardiol 2010;145(2):230-2.
17. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial in- farction. J Am Coll Cardiol 2003;41(1):1-7.
18. Genda S, Miura T, Miki T, Ichikawa Y, Shimamoto K. K(ATP) channel opening is an endogenous mechanism of protection against the no-reflow phenomenon but its function is compromised by hypercholesterolemia. J Am Coll Cardiol 2002;40(7):1339-46.
19. Foussas SG, Zairis MN, Lyras AG, Patsourakos NG, Tsirimpis VG, Katsaros K, et al. Early prognostic usefulness of C-reactive protein added to the Thrombolysis In Myocardial Infarction risk score in acute coronary syndromes. Am J Car- diol 2005;96(4):533-7.
20. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation 2008;117(11):1449-59.
21. Rubin DB, Wiener-Kronish JP, Murray JF, Green DR, Turner J, Luce JM, et al. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmo- nary sepsis syndrome. J Clin Invest 1990;86(2):474-80.
22. Stone GW, Webb J, Cox DA, Brodie BR, Qureshi M, Kalynych A, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment el- evation myocardial infarction: a randomized controlled trial. JAMA 2005;293(9):1063-72.
23. Gick M, Jander N, Bestehorn HP, Kienzle RP, Ferenc M, Werner K, et al. Randomized evaluation of the effects of filter-based distal protection on myocardial perfusion and infarct size after primary percutaneous catheter intervention in myo- cardial infarction with and without ST-segment elevation. Circulation 2005;112(10):1462-9.
24. Ali A, Cox D, Dib N, Brodie B, Berman D, Gupta N, et al. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarc- tion: 30-day results from a multicenter randomized study. J Am Coll Cardiol 2006;48(2):244-52.
25. de Lemos JA, Antman EM, Gibson CM, McCabe CH, Giugliano RP, Murphy SA, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 2000;101(3):239-43.
26. Giri S, Mitchel JF, Hirst JA, McKay RG, Azar RR, Mennett R, et al. Synergy between intracoronary stenting and abciximab in improving angiographic and clinical outcomes of primary angioplasty in acute myocardial infarction. Am J Cardiol 2000;86(3):269-74.
27. Claeys MJ, Bosmans J, De Ceuninck M, Beunis A, Vergauwen W, Vorlat A, Vrints CJ. Effect of intracoronary adenosine infusion during coronary intervention on myocardial reperfu- sion injury in patients with acute myocardial infarction. Am J Cardiol 2004;94(1):9-13.
28. Ishibashi F, Saito T, Hokimoto S, Noda K, Moriyama Y, Oshima S. Combined revascularization strategy for acute myocardial infarction in patients with intracoronary thrombus: preceding intracoronary thrombolysis and subsequent me- chanical angioplasty. Jpn Circ J 2001;65(4):251-6.
29. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000;36(4):1202-9.
30. Jeong YH, Kim WJ, Park DW, Choi BR, Lee SW, Kim YH, et al. Serum B-type natriuretic peptide on admission can predict the 'no-reflow' phenomenon after primary drug-eluting stent implantation for ST-segment elevation myocardial in- farction. Int J Cardiol 2010;141(2):175-81.